Contrasting effects of intervention with ETa and ETb receptor antagonists in hypertension induced by angiotensin II and high-salt diet

Canadian Journal of Physiology and Pharmacology

Volumn 88, Issue 8, 2010, Pages 802-807

  Boesen, Erika I ^a   Pollock, Jennifer S ^a   Pollock, David M ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

A 192621; ABT 627; Angiotensin II; Endothelin; Hypertension; Kidney

Indexed keywords

4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; ALBUMIN; ANGIOTENSIN II; ATRASENTAN; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRATE; NITRITE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; SIGNAL TRANSDUCTION;

ACUTE KIDNEY INJURY; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HYPERTENSION; MALE; NITRATES; NITRITES; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; SODIUM CHLORIDE, DIETARY; TREATMENT OUTCOME;

EID: 78650200856     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/Y10-051     Document Type: Article

References (32)

1. Alexander, B.T., Cockrell, K.L., Rinewalt, A.N., Herrington, J.N., and Granger, J.P. 2001. Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280(5): R1388-R1392. PMID:11294758.
2. Allcock, G.H., Venema, R.C., and Pollock, D.M. 1998. ETA receptor blockade attenuates the hypertension but not renal dysfunction in DOCA-salt rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 275: R245-R252.
3. Ballew, J.R., and Fink, G.D. 2001a. Role of endothelin ETB receptor activation in angiotensin II-induced hypertension: effects of salt intake. Am. J. Physiol. Heart Circ. Physiol. 281(5): H2218-H2225. PMID:11668086.
4. Ballew, J.R., and Fink, G.D. 2001b. Role of ET(A) receptors in experimental ANG II-induced hypertension in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281(1): R150-R154. PMID:11404288.
5. Barton, M., d'Uscio, L.V., Shaw, S., Meyer, P., Moreau, P., and Luscher, T.F. 1998a. ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension, 31(1 Pt. 2): 499-504. PMID:9453352.
6. Barton, M., Shaw, S., d'Uscio, L.V., Moreau, P., and Luscher, T.F. 1998b. Differential modulation of the renal and myocardial endothelin system by angiotensin II in Vivo. Effects of chronic selective ETA receptor blockade. J. Cardiovasc. Pharmacol. 31(Suppl. 1): S265-S268. doi:10.1097/00005344-199800001-00075. PMID:9595456.
7. Black, S.M., Mata-Greenwood, E., Dettman, R.W., Ovadia, B., Fitzgerald, R.K., Reinhartz, O., et al. 2003. Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow. Circulation, 108(13): 1646-1654. doi:10. 1161/01.CIR.0000087596.01416.2F. PMID:12963646.
8. Cardillo, C., Kilcoyne, C.M., Waclawiw, M., Cannon, R.O., 3rd, and Panza, J.A. 1999. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension, 33(2): 753-758. PMID:10024340.
9. Chen, X.L., Tummala, P.E., Olbrych, M.T., Alexander, R.W., and Medford, R.M. 1998. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ. Res. 83(9): 952-959. PMID:9797345.
10. d'Uscio, L.V., Moreau, P., Shaw, S., Takase, H., Barton, M., and Luscher, T.F. 1997. Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension, 29(1 Pt. 2): 435-441. PMID:9039139.
11. Elmarakby, A.A., Quigley, J.E., Pollock, D.M., and Imig, J.D. 2006. Tumor necrosis factor a blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension, 47(3): 557-562. doi:10.1161/01.HYP.0000198545.01860.90. PMID:16415373.
12. Fujitani, Y., Ueda, H., Okada, T., Urade, Y., and Karaki, H. 1993. A selective agonist of endothelin type B receptor, IRL 1620, stimulates cyclic GMP increase via nitric oxide formation in rat aorta. J. Pharmacol. Exp. Ther. 267(2): 683-689.PMID:7504100.
13. Fukuroda, T., Fujikawa, T., Ozaki, S., Ishikawa, K., Yano, M., and Nishikibe, M. 1994. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem. Biophys. Res. Commun. 199(3): 1461-1465. doi:10.1006/bbrc.1994.1395. PMID:8147891.
14. Gratton, J.P., Cournoyer, G., Loffler, B.M., Sirois, P., and D'Orléans-Juste, P. 1997. ET(B) receptor and nitric oxide synthase blockade induce BQ-123-sensitive pressor effects in the rabbit. Hypertension, 30(5): 1204-1209. PMID:9369277.
15. Herizi, A., Jover, B., Bouriquet, N., and Mimran, A. 1998. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension, 31(1): 10-14. PMID:9449383.
16. Lau, Y.E., Galligan, J.J., Kreulen, D.L., and Fink, G.D. 2006. Activation of ETB receptors increases superoxide levels in sympathetic ganglia in vivo. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290(1): R90-R95.PMID:16179487.
17. Montezano, A.C., Callera, G.E., Mota, A.L., Fortes, Z.B., Nigro, D., Carvalho, M.H., et al. 2005. Endothelin-1 contributes to the sexual differences in renal damage in DOCA-salt rats. Peptides, 26(8): 1454-1462.doi:10.1016/j.peptides.2005.03.038.PMID:16042985.
18. Moreau, P., d'Uscio, L.V., Shaw, S., Takase, H., Barton, M., and Luscher, T.F. 1997. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation, 96(5): 1593-1597.PMID:9315552.
19. Muller, D.N., Mervaala, E.M., Schmidt, F., Park, J.K., Dechend, R., Genersch, E., et al. 2000. Effect of bosentan on NF-kB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension, 36(2): 282-290.PMID:10948091.
20. Opgenorth, T.J., Adler, A.L., Calzadilla, S.V., Chiou, W.J., Dayton, B.D., Dixon, D.B., et al. 1996. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J. Pharmacol. Exp. Ther. 276(2): 473-481. PMID:8632312.
21. Pollock, D.M., and Pollock, J.S. 2001. Evidence for endothelin involvement in the response to high salt. Am. J. Physiol. Renal Physiol. 281(1): F144-F150. PMID:11399655.
22. Pollock, D.M., Allcock, G.H., Krishnan, A., Dayton, B.D., and Pollock, J.S. 2000. Upregulation of endothelin B receptors in kidneys of DOCA-salt hypertensive rats. Am. J. Physiol. Renal Physiol. 278(2): F279-F286. PMID:10662732.
23. Rajagopalan, S., Laursen, J.B., Borthayre, A., Kurz, S., Keiser, J., Haleen, S., et al. 1997. Role for endothelin-1 in angiotensin II mediated hypertension. Hypertension, 30(1 Pt. 1): 29-34. PMID: 9231817.
24. Rothermund, L., Kossmehl, P., Neumayer, H.H., Paul, M., and Kreutz, R. 2003. Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension. J. Hypertens. 21(12): 2389-2397.doi:10.1097/00004872-200312000-00028. PMID:14654760.
25. Sasser, J.M., Pollock, J.S., and Pollock, D.M. 2002. Renal endothelin in chronic angiotensin II hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283(1): R243-R248. PMID:12069950.
26. Sasser, J.M., Sullivan, J.C., Hobbs, J.L., Yamamoto, T., Pollock, D.M., Carmines, P.K., and Pollock, J.S. 2007. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J. Am. Soc. Nephrol. 18(1): 143-154. doi:10.1681/ASN.2006030208. PMID:17167119.
27. Tanifuji, C., Suzuki, Y., Geot, W.M., Horikoshi, S., Sugaya, T., Ruiz-Ortega, M., et al. 2005. Reactive oxygen species-mediated signaling pathways in angiotensin II-induced MCP-1 expression of proximal tubular cells. Antioxid. Redox Signal. 7(9-10): 1261-1268. doi:10.1089/ars.2005.7.1261. PMID:16115031.
28. von Geldern, T.W., Tasker, A.S., Sorensen, B.K., Winn, M., Szczepankiewicz, B.G., Dixon, D.B., et al. 1999. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain confor-mational restriction leads to ET(B) selectivity. J. Med. Chem. 42(18): 3668-3678. doi:10.1021/jm990170q. PMID:10479298.
29. Williams, J.M., Pollock, J.S., and Pollock, D.M. 2004. Arterial pressure response to the antioxidant tempol and ETB receptor blockade in rats on a high-salt diet. Hypertension, 44(5): 770-775.doi:10.1161/01.HYP.0000144073.42537.06. PMID:15452035.
30. Williams, J.M., Zhao, X., Wang, M.H., Imig, J.D., and Pollock, D.M. 2005. Peroxisome proliferator-activated receptor-a activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade. Hypertension, 46(2): 366-371. doi:10.1161/01.HYP.0000172755.25382.fc. PMID:15967866.
31. Winn, M., von Geldern, T.W., Opgenorth, T.J., Jae, H.S., Tasker, A.S., Boyd, S.A., et al. 1996. 2,4-Diarylpyrrolidine-3-carboxylic acids - potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722. J. Med. Chem. 39(5): 1039-1048. doi:10.1021/jm9505369. PMID:8676339.
32. Yukimura, T., Yamashita, Y., Miura, K., Kim, S., Iwao, H., Takai, M., and Okada, T. 1994. Renal vasodilating and diuretic actions of a selective endothelin ETB receptor agonist, IRL1620. Eur. J. Pharmacol. 264(3): 399-405.doi:10.1016/0014-2999(94)00501-X. PMID:7698181.